The Food and Drug Administration (FDA) is advising consumers not to purchase or use B-Lipo, a product promoted and sold for weight loss on various websites and in some retail stores.
FDA laboratory analysis confirmed that B-Lipo contains lorcaserin, a controlled substance and the active ingredient in the FDA-approved prescription drug Belviq®, used for chronic weight management in some overweight or obese adults. Lorcaserin may cause psychiatric disturbances and impairments in attention or memory. Also, concomitant use of lorsaserin with certain medications, such as, but not limited to, drugs commonly used to treat depression and migraine, may result in a potentially life-threatening drug interaction.
Bethel Nutritional Consulting, Inc., has issued a press release voluntarily recalling B-Lipo capsules
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of this product to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
- Complete and submit the report Online: www.fda.gov/MedWatch/report.htm
- Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Note: This notification is to inform the public of a growing trend of dietary supplements or conventional foods with hidden drugs and chemicals. These products are typically promoted for sexual enhancement, weight loss, and body building and are often represented as being “all natural.” FDA is unable to test and identify all products marketed as dietary supplements that have potentially harmful hidden ingredients. Consumers should exercise caution before purchasing any product in the above categories.